Proponents say using fermentation processes can help reduce America’s reliance on China and India for key starting materials and active pharmaceutical ingredients.
The CDMO completed three consecutive commercial-scale process performance qualification batches for a monoclonal antibody drug substance at its Hangzhou facility.
